These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29044394)

  • 1. Prediction of cardiovascular risk in patients with familial hypercholesterolaemia.
    Villa G; Wong B; Kutikova L; Ray KK; Mata P; Bruckert E
    Eur Heart J Qual Care Clin Outcomes; 2017 Oct; 3(4):274-280. PubMed ID: 29044394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: A cohort study.
    Iyen B; Qureshi N; Kai J; Akyea RK; Leonardi-Bee J; Roderick P; Humphries SE; Weng S
    Atherosclerosis; 2019 Aug; 287():8-15. PubMed ID: 31181417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
    Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
    Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Disease Risk Associated With Familial Hypercholesterolemia: A Systematic Review of the Literature.
    Wong B; Kruse G; Kutikova L; Ray KK; Mata P; Bruckert E
    Clin Ther; 2016 Jul; 38(7):1696-709. PubMed ID: 27261205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High miR-133a levels in the circulation anticipates presentation of clinical events in familial hypercholesterolaemia patients.
    Escate R; Padró T; Suades R; Camino S; Muñiz O; Diaz-Diaz JL; Sionis A; Mata P; Badimon L
    Cardiovasc Res; 2021 Jan; 117(1):109-122. PubMed ID: 32061123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to implement clinical guidelines to optimise familial hypercholesterolaemia diagnosis and treatment.
    Farnier M; Civeira F; Descamps O;
    Atheroscler Suppl; 2017 Apr; 26():25-35. PubMed ID: 28434482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients.
    Jansen AC; van Aalst-Cohen ES; Tanck MW; Trip MD; Lansberg PJ; Liem AH; van Lennep HW; Sijbrands EJ; Kastelein JJ
    J Intern Med; 2004 Dec; 256(6):482-90. PubMed ID: 15554949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced status of inflammation and endothelial activation in subjects with familial hypercholesterolaemia and their related unaffected family members: a case control study.
    Rahman T; Hamzan NS; Mokhsin A; Rahmat R; Ibrahim ZO; Razali R; Thevarajah M; Nawawi H
    Lipids Health Dis; 2017 Apr; 16(1):81. PubMed ID: 28438163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knowledge gaps in the management of familial hypercholesterolaemia. A UK based survey.
    Schofield J; Kwok S; France M; Capps N; Eatough R; Yadav R; Ray K; Soran H
    Atherosclerosis; 2016 Sep; 252():161-165. PubMed ID: 27451004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated.
    Stock J
    Atherosclerosis; 2019 Nov; 290():138-139. PubMed ID: 31610884
    [No Abstract]   [Full Text] [Related]  

  • 11. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration.
    ; Vallejo-Vaz AJ; Akram A; Kondapally Seshasai SR; Cole D; Watts GF; Hovingh GK; Kastelein JJ; Mata P; Raal FJ; Santos RD; Soran H; Freiberger T; Abifadel M; Aguilar-Salinas CA; Alnouri F; Alonso R; Al-Rasadi K; Banach M; Bogsrud MP; Bourbon M; Bruckert E; Car J; Ceska R; Corral P; Descamps O; Dieplinger H; Do CT; Durst R; Ezhov MV; Fras Z; Gaita D; Gaspar IM; Genest J; Harada-Shiba M; Jiang L; Kayikcioglu M; Lam CS; Latkovskis G; Laufs U; Liberopoulos E; Lin J; Lin N; Maher V; Majano N; Marais AD; März W; Mirrakhimov E; Miserez AR; Mitchenko O; Nawawi H; Nilsson L; Nordestgaard BG; Paragh G; Petrulioniene Z; Pojskic B; Reiner Ž; Sahebkar A; Santos LE; Schunkert H; Shehab A; Slimane MN; Stoll M; Su TC; Susekov A; Tilney M; Tomlinson B; Tselepis AD; Vohnout B; Widén E; Yamashita S; Catapano AL; Ray KK
    Atheroscler Suppl; 2016 Dec; 22():1-32. PubMed ID: 27939304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing.
    Humphries SE; Cranston T; Allen M; Middleton-Price H; Fernandez MC; Senior V; Hawe E; Iversen A; Wray R; Crook MA; Wierzbicki AS
    J Mol Med (Berl); 2006 Mar; 84(3):203-14. PubMed ID: 16389549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and meta-analysis.
    Oosterveer DM; Versmissen J; Yazdanpanah M; Hamza TH; Sijbrands EJ
    Atherosclerosis; 2009 Dec; 207(2):311-7. PubMed ID: 19439299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk stratification in familial hypercholesterolaemia.
    Sharifi M; Rakhit RD; Humphries SE; Nair D
    Heart; 2016 Jul; 102(13):1003-8. PubMed ID: 27126396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case-finding and genetic testing for familial hypercholesterolaemia in primary care.
    Qureshi N; Akyea RK; Dutton B; Humphries SE; Abdul Hamid H; Condon L; Weng SF; Kai J;
    Heart; 2021 Dec; 107(24):1956-1961. PubMed ID: 34521694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG; Dufour R; Davignon J; Baass A
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia.
    Silva PR; Jannes CE; Marsiglia JD; Krieger JE; Santos RD; Pereira AC
    Atherosclerosis; 2016 Jul; 250():144-50. PubMed ID: 27214396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
    deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
    Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia.
    Jarauta E; Mateo-Gallego R; Gilabert R; Plana N; Junyent M; de Groot E; Cenarro A; Masana L; Ros E; Civeira F
    Nutr Metab Cardiovasc Dis; 2012 Jul; 22(7):591-7. PubMed ID: 21196102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.
    Haralambos K; Whatley SD; Edwards R; Gingell R; Townsend D; Ashfield-Watt P; Lansberg P; Datta DB; McDowell IF
    Atherosclerosis; 2015 May; 240(1):190-6. PubMed ID: 25797312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.